Abstract: The present disclosure provides a method for recycling urea-formaldehyde (UF) from a wood-based panel. In the present disclosure, the UF is depolymerized by an ultrasonic treatment, and depolymerized UF can be reused for UF manufacture and wood-based panel production. The recycled and treated UF can be repeatedly used in wood-based panel manufacture without affecting performances of the wood-based panel. UF-glued wood-based panels can be recycled, and a recycled wood-based panel raw material can replace at least 50% of a non-recycled wood-based raw material for particle board production without affecting performances of the wood-based panel.

Abstract: The present disclosure provides example traffic routing methods, apparatuses, and systems. One example method includes determining, by a session management network element, a routing rule, where the routing rule indicates a first traffic steering entity to send a first traffic to a first function entity, or send a second traffic to a second function entity or an access device, where the first traffic is a traffic on which first traffic steering control is to be performed, and the second traffic is a traffic on which the first traffic steering control has been performed. The routing rule is sent by the session management network element to the first traffic steering entity in a session management process.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: A heat exchanger includes a fin set formed by a plurality of fins stacked together and a refrigerant pipe set passing through the fin set. The fin set includes a connection member, and a first fin member and a second fin member connected to each other via the connection member. An included angle between the first fin member and the second fin member is larger than zero. The first fin member and the second fin member are arranged at two sides, respectively, of a notch of the fin set. The notch is located at an air input side and/or an air output side of the connection member.

Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Abstract: This disclosure relates to LPA antagonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: In some implementations, a storage node receives data processing instructions from a compute node of a network architecture. The storage node detects a Directed Acyclic Graph (DAG) within the data processing instructions. The DAG includes a plurality of data processing operations arranged within the DAG according to an execution. The data processing operations further include user-defined function (UDF) information associated with a UDF. The storage node may retrieve a first data object from an object store of the distributed storage node based on object keys information within the plurality of data processing operations. The storage node may execute the plurality of data processing operations using the retrieved first data object to generate a DAG execution result, the executing of the plurality of data processing operations based on the execution order. The storage node may communicate the DAG execution result to the compute node in response to the data processing instructions.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The disclosure relates to technology for acceleration of GPUs in cloud. Instructions for a computational task are accessed. An allocation of data and instructions is calculated based on the data, the instructions, and dynamic GPU resources. The data and the instructions are provided to the GPUs in accordance with the allocation, which includes scheduling a set of instructions for parallel computation of an operation of the computational task on multiple sub-matrices of a data matrix. Separate portions of information are stored into corresponding different regions of non-transitory memory of a processor core to provide concurrent access to the multiple sub-matrices to the processor core. Each sub-matrix corresponds to a portion of the data matrix for which an operation of the computational task is to be performed. Each sub-matrix contains an element in the data matrix in common with another sub-matrix of the data matrix.

Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: An integrated light-emitting device and a fabricating method thereof. The integrated light-emitting device includes a first electrode, an insulating layer, a second electrode, a light-emitting layer, and a third electrode which are sequentially laminated; the first electrode, the insulating layer, the second electrode, and the third electrode together constitute a field effect transistor unit, and the first electrode, the second electrode and the third electrode are respectively a gate, a source and a drain of the field effect transistor unit, and a surface of the insulating layer adjacent to the second electrode is provided with a nano-pit array structure configured for condensing light; and the second electrode, the light-emitting layer and the third electrode together constitute a light-emitting unit, the light-emitting unit configured to emit light toward the first electrode along the second electrode.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present invention relates to a compound of formula (X) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the compound and a use.